Willis-Owen, Saffron A. G.
Domingo-Sabugo, Clara
Starren, Elizabeth
Liang, Liming
Freidin, Maxim B.
Arseneault, Madeleine
Zhang, Youming
Lu, Shir Kiong
Popat, Sanjay
Lim, Eric
Nicholson, Andrew G.
Riazalhosseini, Yasser
Lathrop, Mark
Cookson, William O. C.
Moffatt, Miriam F.
Article History
Received: 9 December 2020
Accepted: 26 May 2021
First Online: 14 June 2021
Competing interests
: A.N. reports personal fees from Merck, Boehringer Ingelheim, Novartis, Astra Zeneca, Bristol Myer Squib, Roche, Abbvie and Oncologica, as well as grants and personal fees from Pfizer outside the submitted work. E.L. reports personal fees from Glaxo Smith Kline, Pfizer, Novartis, Covidien, Roche, Lily Oncology, Boehringer Ingelheim, Medela, Astra Zeneca and Ethicon; Grants and personal fees from ScreenCell; Grants from Clearbridge Biomedics, Illumina and Guardant Health, outside the submitted work. In addition, E.L. has patents P52435GB and P57988GB issued to Imperial Innovations, is the Director of lung screening at the Cromwell Hospital, and is CI for both VIOLET NIHR HTA (13/04/03) and MARS 2 NIHR HTA (15/188/31). S.P. reports personal fees from BMS, Roche, Takeda, AstraZeneca, Pfizer, MSD, EMD, Serono, Guardant Health, Abbvie, Boehringer Ingelheim, OncLive, Medscape, Incyte, Paradox Pharmaceuticals and Eli Lilly outside the submitted work. The other authors declare no competing interests.